Skip to main content Skip to footer

Orexo press releases

Interim report, January-March 2012

27 April 2012 at 08:00 – Regulatory – Report – Q1

Interim report, January-March 2012

Report from Orexo AB’s Annual General Meeting, 11 April 2012

11 April 2012 at 18:30 – Regulatory – General Meeting

Report from Orexo AB’s Annual General Meeting, 11 April 2012

Notice of Annual General Meeting of Orexo

12 March 2012 at 10:00 – Regulatory – General Meeting

Notice of Annual General Meeting of Orexo

Orexo AB focuses its business and reduces costs

6 March 2012 at 11:00 – Regulatory

Orexo AB focuses its business and reduces costs

Interim Report January-December 2011

31 January 2012 at 08:31 – Regulatory – Report – Q4

Interim Report January-December 2011

Positive study results for OX27

20 December 2011 at 13:00 – Regulatory

Positive study results for OX27

Interim report, January-September 2011

9 November 2011 at 08:00 – Regulatory – Report – Q3

Interim report, January-September 2011

Orexo appoints Peter Edman as Chief Scientific Officer

4 October 2011 at 09:00 – Regulatory

Orexo appoints Peter Edman as Chief Scientific Officer

Interim report January-June 2011

10 August 2011 at 08:00 – Regulatory – Report – Q2

Interim report January-June 2011

Sublinox (Edluar) approved in Canada

25 July 2011 at 08:00 – Regulatory

Sublinox (Edluar) approved in Canada

Orexo announces addendum to prospectus made public

15 June 2011 at 08:30 – Regulatory

Orexo announces addendum to prospectus made public

Abstral® launches in Canada

14 June 2011 at 14:00 – Regulatory

Abstral® launches in Canada

Report from Orexo AB’s extraordinary shareholders’ meeting, 27 May 2011

27 May 2011 at 13:00 – Regulatory – General Meeting

Report from Orexo AB’s extraordinary shareholders’ meeting, 27 May 2011

President and CEO

Nikolaj Sørensen

EVP & Chief Financial Officer

Fredrik Järrsten